(Gastric Cancer) Is Enhertu Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- November 24, 2022
- Reading time: 1 minute
On November 15, 2022, Kensei Yamaguchi and colleagues from Cancer Institute Hospital published results in the Journal of Clinical Oncology from the DESTINY-Gastric01 Phase II clinical trial evaluating Enhertu (trastuzumab deruxtecan) in HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer patients with two or more prior lines of therapy.
The DESTINY-Gastric01 Phase II trial was a multicenter open-label study that randomized HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy in a 2:1 ratio to the Enhertu arm (6.4 mg/kg every 3 weeks) or chemotherapy arm. Primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate, progression-free survival (PFS), and overall survival (OS). Patients were classified into cohort 1 (N=21) and cohort 2 (N=24) based on HER2 classification.
Results:
ORR: cohort 1 26.3% / cohort 2 9.5%. Tumor shrinkage rate: cohort 1 68.4% (N=13) / cohort 2 60.0% (N=12).
Median OS: cohort 1 7.8 months / cohort 2 8.5 months. Median PFS: cohort 1 4.4 months / cohort 2 2.8 months.
Safety:
Grade ≥3 adverse events included anemia (cohort 1: 30.0% / cohort 2: 29.2%), neutropenia (cohort 1: 25.0% / cohort 2: 29.2%), and decreased appetite (cohort 1: 20.0% / cohort 2: 20.8%). Drug-induced interstitial lung disease was confirmed in one patient per cohort.
Based on the DESTINY-Gastric01 trial results, Kensei Yamaguchi and colleagues concluded that Enhertu demonstrated clinically meaningful antitumor activity in HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00575
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4